Eli Lilly’s experimental weight‑loss drug retatrutide cuts knee‑osteoarthritis pain in two Phase 3 trials
Eli Lilly reported that its triple‑agonist retatrutide produced substantial weight loss and reduced knee‑osteoarthritis pain in two late‑stage studies, TRIUMPH‑4 (68 weeks) and TRIUMPH‑1‑OA (80 weeks). In TRIUMPH‑4, 9 mg and 12 mg doses lowered WOMAC pain scores by 3.96 and 3.74 points versus 2.12 for placebo, while participants lost about 20 % of body weight. In TRIUMPH‑1‑OA, the 4 mg, 9 mg and 12 mg doses cut pain scores by 3.22, 3.48 and 3.64 points respectively, compared with a 1.87‑point drop for placebo, and produced weight loss of 17.5 %‑24.8 %. The trials enrolled a total of 1,019 obese adults without diabetes who also had knee osteoarthritis.
Why it matters
The company says the data could support regulatory filings for a new indication that addresses both obesity and knee‑osteoarthritis, potentially expanding Lilly’s market for retatrutide beyond weight‑loss alone. Analysts note that a successful indication could add a sizable revenue stream if the drug gains approval for pain relief (source).
Key facts
- 1TRIUMPH‑4 enrolled 445 participants who received 9 mg, 12 mg or placebo for 68 weeks. medicalnewstoday.com
- 2TRIUMPH‑1‑OA enrolled 574 participants who received 4 mg, 9 mg, 12 mg or placebo for 80 weeks. medicalnewstoday.com
- 3The two trials together included 1,019 participants. healthandme.com
- 4In TRIUMPH‑4, the 9 mg dose reduced WOMAC pain score by 3.96 points versus 2.12 for placebo. medicalnewstoday.com
- 5In TRIUMPH‑4, the 12 mg dose reduced WOMAC pain score by 3.74 points versus 2.12 for placebo. medicalnewstoday.com
- 6In TRIUMPH‑1‑OA, the 4 mg dose reduced WOMAC pain score by 3.22 points versus 1.87 for placebo. healthandme.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.